Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 to 55 years of age, inclusive.~* Body weight ranging from 50 to 100 kilograms (kg) and a body mass index (BMI) ≤ 30 kg/m2.~* Healthy as determined by unremarkable medical history, physical examination, vital signs, laboratory evaluations, electrocardiogram (ECG), and a 24-hour screening ECG telemetry.~* Willing to refrain from strenuous exercise or contact sports during the study.~* Female subjects must be surgically sterile or at least 2 years postmenopausal, or using an effective contraceptive method (intrauterine device, hormonal contraceptive, or double-barrier method).~Exclusion Criteria:~* Any clinically significant illness during the 30 days prior to randomization.~* Any history of allergy to buprenorphine, any excipient of BTDS, opioids, psychotropic or hypnotic drugs, and/or moxifloxacin or any member of the quinolone class of drugs.~* A clinically significant history of allergic reaction to wound dressings or bandages.~* Any medical or surgical conditions which might interfere with drug absorption (transdermal or gastrointestinal), distribution, metabolism, or excretion.~* Abnormalities on physical examination, vital signs, ECG, or clinical laboratory values, unless those abnormalities are judged to be clinically insignificant by the Investigator.~* Any cardiovascular disorders, including hypertension.~* Oxygen saturation (SpO2) ≤ 94% as measured by pulse oximetry.~* Any personal or family history of prolonged QT interval or disorders of cardiac rhythm.~* Abnormal cardiac condition denoted by any of the following:~* QT interval ≥ 450 milliseconds (msec).~* PR interval \> 240 msec or ≤ 110 msec.~* Evidence of second- or third-degree atrioventricular (AV) block.~* Pathological Q-waves (defined as Q-wave \> 40 msec or depth \> 0.5 mV).~* Evidence of ventricular preexcitation, complete left bundle branch block, right bundle branch block (RBBB), or incomplete RBBB.~* A resting heart rate outside the range of 50 to 85 beats per minute (bpm).~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BTDS (Type: EXPERIMENTAL): Buprenorphine transdermal patches 5, 10, 20, and 2 \* 20 mcg/h.
- Placebo TDS (Type: PLACEBO_COMPARATOR): Matching placebo transdermal patches 5, 10, 20 and 2 \* 20.
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin hydrochloride 400 mg tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).